GLYCEMIC IMBALANCES DURING NEOPLASTIC DISEASES
Réf. 014 M
Ferdaous BELAID1, Imen BEN JDIDIA1, Amira DALDOUL1, Sonia ZAIED1, Amani CHERIF 1
1 : Maternity center , CHU FATTOUMA BOURGUIBA MONASTIR
Voir le poster complet
Résumé du poster
Introduction : Co-occurrence of solid cancer and diabetes can lead to glycemic imbalances, potentially affecting morbidity and mortality related to diabetes.
Both doctors and patients may be less diligent in glycemic control due to the focus on cancer management, resulting in disturbances in biochemical parameters such as HbA1C.The study attempt to investigate the glycemic imbalances in diabetic patients and the pharmacological factors contributing to these imbalances.
Matériels & méthode : The study population consisted of 50 patients (29 female and 21 man) with solid tumors and diabetes mellitus.These patients were suffering from 6 major types of solid tumors: respiratory system tumors (n=7),Gastro-intestinal tumors(n=8),female reproductive system tumors (n=26), male reproductive system (n=4),Tumors in the head and neck region (n=1),urinary tract tumors (n=4). The HbA1C values were measured before chemotherapy (T0), after 3 months of chemotherapy (T3) , and by the end of 6 months of chemotherapy (T6). The objectives of glycemic control were determined based on patient profiles, age, duration of diabetes, life expectancy, and associated comorbidities, following the recommendations of the French Health Authority (HAS).
SPSS 23.0 program for Windows was used for statistical analysis.
Résultats & discussion : Patients undergoing chemotherapy for solid tumors experience disturbed HbA1C and blood glucose levels, with a general upward trend.
Multivariate analysis of variables related to glycemic balance at three different time points : before chemotherapy(T0), after three months(T3) and by the end of 6 months of chemotherapy(T6), showed a correlation between tumors in the male reproductive system and an increase in HbA1C up to 45% in T6 (9.62%Hb in T0 to 13.98%Hb in T6) , with a significance of 0.016. As previous study, these findings are suggesting that the use of anti-androgen hormone therapy may have an impact on glycemic balance in men especially with prostate cancer.
The patients were divided into two subgroups based on their chemotherapy: one receiving 5-Fluorouracil or pyrimidine analogues (n=28) and the other receiving other cytotoxic molecules (n=22). The first group had a significant increase of 2% Hb units on HbA1C levels by the end of 6 months of chemotherapy in comparision with initial levels. In fact, the use of 5-FU and analogues can cause disruptions in glycemic balance by affecting the production and/or sensitivity of insulin and other hormones that regulate blood sugar levels.
Conclusion : It is important to consider the potential side effects of chemotherapy drugs on glycemic balance, especially in patients who already have diabetes or other blood sugar disorders.Healthcare providers may need to monitor blood sugar levels more closely in patients receiving 5-FU and analogues to prevent and manage any disruptions in glycemic balance.
Mots clés : Chemotherapy, solid tumors, Fluorouracil, HbA1C
Both doctors and patients may be less diligent in glycemic control due to the focus on cancer management, resulting in disturbances in biochemical parameters such as HbA1C.The study attempt to investigate the glycemic imbalances in diabetic patients and the pharmacological factors contributing to these imbalances.
Matériels & méthode : The study population consisted of 50 patients (29 female and 21 man) with solid tumors and diabetes mellitus.These patients were suffering from 6 major types of solid tumors: respiratory system tumors (n=7),Gastro-intestinal tumors(n=8),female reproductive system tumors (n=26), male reproductive system (n=4),Tumors in the head and neck region (n=1),urinary tract tumors (n=4). The HbA1C values were measured before chemotherapy (T0), after 3 months of chemotherapy (T3) , and by the end of 6 months of chemotherapy (T6). The objectives of glycemic control were determined based on patient profiles, age, duration of diabetes, life expectancy, and associated comorbidities, following the recommendations of the French Health Authority (HAS).
SPSS 23.0 program for Windows was used for statistical analysis.
Résultats & discussion : Patients undergoing chemotherapy for solid tumors experience disturbed HbA1C and blood glucose levels, with a general upward trend.
Multivariate analysis of variables related to glycemic balance at three different time points : before chemotherapy(T0), after three months(T3) and by the end of 6 months of chemotherapy(T6), showed a correlation between tumors in the male reproductive system and an increase in HbA1C up to 45% in T6 (9.62%Hb in T0 to 13.98%Hb in T6) , with a significance of 0.016. As previous study, these findings are suggesting that the use of anti-androgen hormone therapy may have an impact on glycemic balance in men especially with prostate cancer.
The patients were divided into two subgroups based on their chemotherapy: one receiving 5-Fluorouracil or pyrimidine analogues (n=28) and the other receiving other cytotoxic molecules (n=22). The first group had a significant increase of 2% Hb units on HbA1C levels by the end of 6 months of chemotherapy in comparision with initial levels. In fact, the use of 5-FU and analogues can cause disruptions in glycemic balance by affecting the production and/or sensitivity of insulin and other hormones that regulate blood sugar levels.
Conclusion : It is important to consider the potential side effects of chemotherapy drugs on glycemic balance, especially in patients who already have diabetes or other blood sugar disorders.Healthcare providers may need to monitor blood sugar levels more closely in patients receiving 5-FU and analogues to prevent and manage any disruptions in glycemic balance.
Mots clés : Chemotherapy, solid tumors, Fluorouracil, HbA1C